The discovery of synthetic proteolytic peptide

Rina Nakamura [1,2], **Motomi Konishi**[1], **Masanari Taniguchi**[1], **Yusuke Hatakawa**[1] **and Toshifumi Akizawa** [1,2,] *

[1] Laboratory of Clinical Analytical Chemistry, Faculty of Pharmaceutical Sciences, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan; momizit0510@gmail.com

[2] O-Force Co., Ltd., 2-12-31 Shodai-Nakamati, Hirakata, Osaka 573-1152, Japan; momizit0510@gmail.com

*   Correspondence: momizit0510@gmail.com; Tel.: +81-80-6132-4938

Abstract: After screening nearly 1000 synthetic peptides, a synthetic peptide termed JAL-AK22 (KYEGHWYPEKPYKGSGFRCIHI) derived from the BoxA domain in Tob1 protein was found to activate both unfolded and folded proMMP-7. In addition, JAL-AK22 showed auto-proteolytic activity. Interestingly, the smaller derivative of JAL-AK22 termed JAL-TA9 (YKGSGFRMI) also possessed auto-proteolytic activity and cleaved 2 fragment peptides (MMP18-33 and MMP18-40) derived from the prodomain of proMMP-7 under physiological conditions. These proteolytic activities were inhibited by AEBSF, a serine protease inhibitor. Our results demonstrate that a small synthetic peptide consisting of only 9 amino acids has serine protease-like activity and activates proMMP-7 by cleaving the prodomain region. We thus propose calling small peptides possessing with protease-like activity Catalytides (catalytic peptides). We expect that our findings will stimulate the development of novel Catalytides and related applications.

Keywords: Catalytide, serine protease-like peptide, Tob1

1. Introduction

We reported the microplate assay method for screening the possible inhibitors of MMPs (MMPIs), which are thought to be critically involved in oncogenesis, using with activated recombinant matrix metalloproteinases (actMMPs) and a fluorescence quenching substrate (3163-v) [1-3]. To prepare activated MMP-7 (actMMP-7) from unfold proMMP-7 (u-proMMP-7) expressed in *Escherichia coli*, refolding step and proteolytic cleavage of prodomain were necessary. The activity of actMMP-7 was monitored with fluorescence intensity produced from 3163-v; thus, the fluorescence intensity reflects the level of cleavage and thereby u-proMMP-7 activation (Scheme 1a). We thought that the chaperone-like peptide could be screened by the microplate assay method. After screening nearly 1,000 peptides, some peptides were found to activate u-proMMP-7 (Scheme 1b). The most potent peptide is termed JAL-AK22 (KYEGHWYPEKPYKGSGFRCIHI), comprising 22 amino acids derived from the BoxA domain in the Tob1 protein (Figure S1a), a membrane-type tyrosine kinase, was found to activate u-proMMP-7, in contrast to the initial expectation (data not shown). The protein encoded by Tob1 is a member of the Tob/BTG family consisted of BTG1, BTG2/Tis21/PC3, ANA/BTG3, BTG4/PC3B and Tob2. The N-terminus region of Tob/BTG family is a highly conserved homology domain that contains BoxA, B and C. According to recent reports, these proteins display antiproliferative activity in a variety of cell types and are involved in the regulation of tumorigenesis [4-6]. However, the role of the BoxA domain of Tob/BTG family protein is still unclear, and there have been no reports of protease activity. Enzymes are generally macromolecular proteins, acting alone or in large complexes. To the best of our knowledge, protease-like activity has never been reported in very small synthetic peptides. In this study, we describe the identification of a small protease-like peptide termed as Catalytide.

45 **2. Results**

46 *2.1. Screening of proteolytic peptide, JAL-AK22*

47 2.1.1. Screening of proteolytic peptide

48 Our first aim of this study was to find the chaperone-like peptide, which could affect the
49 refolding of u-proMMP-7 [7]. The reaction mixture containing u-proMMP-7 and fluorescence
50 substrate (3163-v) was incubated at 37 °C in assay buffer. The fluorescence intensity was measured
51 with excitation at 320 nm and emission at 390 nm (Scheme 1b). After screening nearly 1000 synthetic
52 peptides in our peptide library, the synthetic peptide derived from BoxA region of Tob1 protein
53 termed JAL-AK22 (KYEGHWYPEKPYKGSGFRCIHI) (Figure S1a) was found as the activator of
54 u-proMMP-7 (data not shown). However, it was unclear whether JAL-AK22 affected the refolding
55 (Scheme 1b) or cleavage (Scheme 1c) of the prodomain of proMMP-7. To clarify this question, we
56 next analyzed the effect of JAL-AK22 on the activation of folded proMMP-7 (f-proMMP-7), which
57 was prepared by renaturation of u-proMMP-7 (Scheme 1a). As shown in Figure 1, JAL-AK22
58 significantly enhanced the activation of f-proMMP-7 but slightly reduced the activity of preactivated
59 MMP-7 (actMMP-7) activated by trypsin (Scheme 1a). The f-proMMP-7 alone showed much slower
60 activation apparently due to spontaneous auto-catalysis. These results indicated that JAL-AK22
61 could activate f-proMMP-7 by proteolytic cleavage of proMMP-7 rather than refolding of
62 u-proMMP-7 [8].

63

64

65

Scheme 1. Screening and identification of proteolytic peptides (a) Screening of MMP inhibitor (b) Screening of chaperone-like peptide (c) Screening of proteolytic peptide

68

69

70

Figure 1. Activation of folded proMMP-7 by JAL-AK22

72

73   2.1.2. Auto-proteolytic activity

74   In a preliminary analysis of the reaction mixture described above, we noticed a decrease in the
75   JAL-AK22 level after incubation and thus decided to examine its auto-proteolytic activity with or
76   without human serum albumin (HSA).   JAL-AK22 was incubated alone at 37 °C in PBS (pH 7.4),
77   and the incubation mixture was analyzed by HPLC (Figure 2a).   The original amount of JAL-AK22
78   decreased in a time-dependent manner, strongly suggesting that JAL-AK22 has auto-proteolytic
79   activity. The peaks (1-4) in the chromatogram that appeared after 5 days were collected (Figure 2b).
80   By MS analyses, 7 kinds of fragment peptides derived from JAL-AK22 were identified in the reaction
81   mixture (Table 1).

82

83   **Figure 2.** Identification of auto-proteolysis activity of JAL-AK22 (a) time dependent
84   analysis (b) peak collection

85   **Table 1.** Identification of fragment peptides of JAL-AK22

Peak	Fragment	Theoretical MS	Experimental MS
1	KYEGHWYPEKPYK	1723.84	1722.8665
1	KYEGHWYPEKPYKGS	1867.89	1866.9345
2	KYEGHWYPEKPYKGSGFR	2228.08	2228.1138
3	KYEGHWYPEKPY	1595.74	1595.7560
4	EKPYKGSGFRC (YKGSGFRCIHI) I	2661.35	2661.3766
4	HWYPEKPYKGSGFRC (RCIH) IHI	2742.35	2742.3270
4	KYEGHWYPEKPYKGSGFRCIHI (dimmer)	5386.64	5386.6256

86

87   On the other hand, 8 kinds of fragment peptides were identified in the reaction mixture
88   including HSA (Figure 3 and Table 2). These data indicated that JAL-AK22 might possess the
89   auto-proteolytic activity. Interestingly, the decreasing ratio of original JAL-AK22 was higher than
90   that of JAL-AK22 alone (Figure S2). It suggests that the auto-proteolytic activity might be enhanced
91   in the presence of HSA. The cleavage sites of JAL-AK22 in this reaction are summarized in Figure 11.

92   Taken together, we concluded that JAL-AK22 has proteolytic activity and could activate
93   proMMP-7 through proteolytic removal of the prodomain region [6].

94   **Figure 3.** Identification of auto-proteolysis activity of JAL-AK22 with HSA (a) time
95   dependent analysis (b) peak collection

96

97   **Table 2.** Identification of fragment peptides of JAL-AK22 with HSA

Peak	Fragment	Theoretical MS	Experimental MS
1	KYEGH	632.29	631.3216
2	KYEGHWYPEKPYK	1723.84	1722.9005
2	KYEGHWYPEKPYKGS	1867.89	1866.8650
3	KYEGHWYPEKPYKGSGFR	2228.08	2228.1402
4	KYEGHWYPEKPY	1595.74	1595.7788
4	YPEKPYKGSGFR<u>C</u> (SGFR<u>C</u>) I	2210.05	2210.1325
5	EKPYKGSGFR<u>C</u> (KPYKGSGFR<u>C</u>IHI) IHI	3136.64	3136.8076
6	HWYPEKPYKGSGFR<u>C</u> (R<u>C</u>IH) I	2742.35	2742.3695
7	YEGHWYPEKPYKGSGFR<u>C</u> (R<u>C</u>) I	2591.20	2591.3565
7	KYEGHWYPEKPYKGSGFR<u>C</u>IHI (dimmer)	5386.64	5386.7384
8	KYEGHWYPEKPYKGSGFR<u>C</u> (<u>C</u>IHI) IHI	3176.57	3176.6497

98

99

100

101

102   *2.2. Identification of proteolytic peptide, JAL-TA9*

103   2.2.1. Auto-proteolytic activity

104   MS analysis of JAL-AK22 indicated that the Cys residue containing fragment peptides
105   produced by auto-protelytic activity formed the homo/hetero dimers (Table 1 and 2). This reaction is
106   not suitable to identify the proteolytic activity by MS analysis, thus we planed to determine the
107   minimum sequence required for the auto-proteolytic activity. The additional 9 peptides were
108   synthesized and examined the auto-proteolytic activity in the same manner (Figure S2). JAL-TAK22
109   (KYEGHWYPEKPYKGSGFRMIHI), substituted Cys residue to Met, showed the similar
110   auto-proteolytic activity to JAL-AK22. In addition, JAL-TAY11 (YKGSGFRMIHI) showed more
111   potent than JAL-AK22. The proteolytic activities of the shorter peptides comparison of JAL-TA9
112   (YKGSGFRMI) were low. As a result, a 9-mer peptide termed JAL-TA9 was found to show the
113   highest auto-proteolytic activity and further investigated for its proteolytic activity (Figure S3b).

114   The optimal reaction conditions for JAL-TA9 were analyzed by monitoring the
115   auto-proteolytic activity. JAL-TA9 showed potent auto-proteolytic activity between pH 7.0 and 7.5
116   in the presence of HSA in phosphate buffer (Figure S4a). Judging from the effects of various buffers
117   including PBS, Tris-HCl (pH 7.5), phosphate buffer (pH 7.5), assay buffer (pH 7.5) [1, 3], PBS was
118   selected for the following experiments (Figure S4b). Among the temperatures tested (4 °C, room
119   temperature, 37 °C and 70 °C), the maximum activity was observed at 37 °C in PBS (pH 7.4) (Figure
120   S4c).

121   JAL-TA9 (final conc., 0.2 mM) was incubated alone in PBS at 37 °C, and the reaction mixture
122   was analyzed for 5 days by HPLC. The level of JAL-TA9 was decreased in time dependent manner,
123   along with the formation of several peaks in the HPLC chromatogram (Figure 4a). On day 5, we
124   corrected the 10 peaks (J1 - J10) including JAL-TA9 (J9) (Figure 4b) and identified 8 peptides and 1
125   amino acid as derivatives from JAL-TA9 (Table 3).

126

127   **Figure 4.** Identification of auto-proteolysis activity of JAL-TA9 (a) time dependent analysis
128   (b) peak collection

129

130   **Table 3.** Identification of fragment peptides of JAL-TA9

Peak	Fragment	Theoretical MS	Experimental MS
J1	YKGSG	510.24	510.2548
J2	Y	181.19	181.0511
J3	FR	321.18	321.1800
J4	YKGSGFR	813.41	813.4260
J5	YKGSGF	657.31	657.3236
J6	MI	262.14	262.1452
J7	YKGSGFRM	944.45	944.6563
J8	KGSGFRMI	894.47	894.4824
J9	YKGSGFRMI	1057.54	1057.5705
J10	FRMI	565.30	565.3011

131

132   We next examined the auto-proteolytic activity of JAL-TA9 in the presence of HSA (final
133   conc., 0.025 % w/v). The reaction mixture was analyzed every 1 hr for 6 hrs by HPLC (Figure 5a). As
134   expected, similar to JAL-AK22, the auto-catalytic activity of JAL-TA9 was enhanced in presence of
135   HSA (Figure S2b and c). The level of JAL-TA9 was decreased, along with the formation of several
136   peaks in the HPLC chromatogram (Figure 5a).   After 1 hr of incubation, the peak corresponding to
137   JAL-TA9 had decreased and almost disappeared after 6 hrs, with the concomitant detection of
138   several peaks in the chromatogram (Figure 5b).   MS analysis revealed that the new peaks
139   corresponded to new peptides derived from JAL-TA9 (Table 4).   The cleavage sites of JAL-TA9 in
140   the presence or absence of HSA are summarized in Figure 11.   The specificity for these cleavage
141   sites appeared to be less strict and could not be defined definitively.

142　　**Figure 5.** Identification of auto-proteolytic activity of JAL-TA9 with HSA (a) time
143　　dependent analysis (b) peak collection

144

145　　**Table 4.** Identification of fragment peptides of JAL-TA9 with HSA

Peak	Fragment	Theoretical MS	Experimental MS
J1	YKGSG	510.24	510.2548
J2	RMI	148.24	418.2364
J3	KGSGF	494.25	494.2612
J4	YKGSGF	658.32	658.3178
J5	YKGSGFRM	944.45	944.4804
J6	KGSGFRMI	894.47	894.4902
J7	YKGSGFRMI	1057.54	1057.5651
J8	GFRMI	622.33	622.3900

146

147　　　Furthermore, we evaluated the auto-proteolytic activity of JAL-TA9 after filtration of the
148　　reaction mixture to deny that these phenomena were due to the contamination of some bacteria or
149　　another hydrolytic enzymes. The reaction mixture including HSA was filtered using MILLEX-GV
150　　(Millipore, 0.22 μm Filter Unit) and TERUMO Syringe (TERUMO, 26G, 1mL) to remove
151　　contaminates and then analyzed by the same manner to the reaction mixture without filtration. The
152　　chromatograms obtained after incubation for 1 day were the same to those obtained without
153　　filtration (Figure S5). These data proved that the auto-proteolytic activity of JAL-TA9 was not due to
154　　contamination of bacteria.
155　　　In the case of incubation with 4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride
156　　(AEBSF), a serine protease inhibitor, the fragment peptide produced by auto-proteolysis of JAL-TA9
157　　was not appeared on the chromatogram (Figure 6). Peak C in Figure 6b was identified as a complex
158　　with JAL-TA9 by MS/MS analysis (Figure 7).　The peaks marked with a star (*) were not peptides.
159　　These data clearly indicated that JAL-TA9 also possessed proteolytic activity and cleaved its own
160　　sequence, suggesting that JAL-TA9 can act as a serine protease [9-11].
161

162

163

164   **Figure 6.** Chromatograms of the reaction mixture with AEBSF (a) day0 (b) day1, C: YKG<u>S</u>

165   (AEBSF) GFRMI, Theoretical MS: 1240.76, Experimental MS: 1240.6283

166

167

168

169   **Figure 7.** MS/MS analysis of the complexes with JAL-TA9 and AEBSF

170

171

172   2.2.2. Proteolysis of the fragment peptides derived from the prodomain of MMP-7

173   We next examined the proteolytic activity of JAL-TA9 against the fragment peptides derived
174   from the prodomain of MMP-7, which contained the cleavage site during the activation of
175   proMMP-7 *in vivo*.   Two synthetic fragment peptides derived from the prodomain of MMP-7
176   (Figure   S1b),   MMP18-33   (LPLPQEAGGMSELQWE)   and   MMP18-40
177   (LPLPQEAGGMSELQWEQAQDYLK), were incubated with JAL-TA9 in the presence of HSA under
178   similar conditions to those described in Figure 3.

179   Judging from the chromatograms obtained by time dependent analysis, MMP18-33 was stable
180   for 3 days with HSA in PBS (Figure 8a). On the other hand, many peaks were appeared after 1 day
181   incubation in the presence of JAL-TA9 (Figure 8b). To identify these peaks, each peak was collected
182   (Figure 8c) and 6 peaks (M1-6) were identified to the derivatives from MMP18-33 (Table 5).
183   MMP18-40 was also examined according to the same manner, and 7 derivative peptides were
184   identified (Figure 7S).   Their cleavage sites were determined (Figure 11).

185

186   **Figure 8.** Proteolytic cleavage of MMP18-33 by JAL-TA9 (a) MMP18-33 alone (b)
187   MMP18-33 with JAL-TA9 (c) peak collection

188

189

190   **Table 5.** Identification of fragment peptides of MMP18-33

Peak	Fragment	Theoretical MS	Experimental MS
M1	SEL	347.17	347.2215
M2	EAGGM	463.17	463.2255
M3	LPQ	356.21	356.3482
M4	LPLPQ	566.34	566.4081
M5	SELQWE	790.35	790.4393
M6	LPLPQEAG	710.36	709.4516
M6	LPLPQEA	766.42	766.4808

191

192

193

194

195   We also evaluate the proteolytic activity of JAL-TA9 after filtration of the reaction mixture with

196   HSA as well as the auto-proteolytic activity (Figure 5S). The chromatograms profiles obtained time

197   dependent analysis were the same to those obtained without filtration (Figure 9). These data indicate

198   that the proteolysis of MMP18-33 was not caused by the contamination of some bacteria but caused

199   by JAL-TA9.

200

201   **Figure 9.** Proteolytic activity of MMP18-33 by JAL-TA9 with filtration (a) MMP18-33 alone

202   (b) MMP18-33 with JAL-TA9

203

204   We next examined the inhibitory activity of AEBSF against cleavage reactions (Figure 10).

205   MMP18-33 and MMP18-40 were incubated with JAL-TA9 in the presence of AEBSF, and the reaction

206   mixtures were analyzed by HPLC. On the basis of MS analyses, C1 and C2 in Figure 10b were

207   identified as the complex of JAL-TA9 and AEBSF, and C3 was identified as the complex of AEBSF
208   and MMP18-40 (Figure S8). The peaks marked with a star (*) were not peptides and might be the
209   AEBSF products.   These data indicated that cleavage reactions of proMMP-7 fragment peptides by
210   JAL-TA9 were inhibited by AEBSF, similar to the auto-proteolysis (Figure 6).

211
212
213

214   **Figure 10.** Proteolytic cleavage of proMMP-7 fragment peptides by JAL-TA9 in the
215   presence AEBSF (a) MMP18-33 (b) MMP18-40

216
217

218
219   As shown in Figure 11, many cleavage sites by auto-proteolysis were identified with or without
220   HSA. In addition, N-terminus regions of both synthetic peptides were cleaved at preferential sites,
221   suggesting some specificity.   However, the specificity did not appear to be absolute and thus could
222   not be defined definitively, as in the case of auto-proteolysis.
223

224
225

226   **Figure 11.** Comparison of cleavage sites in the presence (▼) or absence of HSA (▲)

227
228   The *K*m and Vmax values of the cleavage reactions of these peptides by JAL-TA9 were 0.17 mM
229   and 0.55 nmol/hr against MMP18-33 and 0.15 mM and 0.78 nmol/hr against MMP18-40, respectively
230   (Figure 12 and S8).   These values were lower than those of known protein enzymes such as
231   chymotrypsin probably due to the absence of a substrate binding site.

232

233   **Figure 12.** Lineweaver-Burk plot (a) MMP-18-33 (b) MMP-18-40

234

235

236

237

238

239
240

241   **3. Discussion**

242   It is the general conception that proteolytic activity is the peculiar to a protein. We also did not
243   have conviction about the existence of proteolytic peptide, therefore we started this project to find a
244   chaperon peptide which could refold the unfolded proMMP-7. In this study, we identified the
245   synthetic peptide possessing the proteolytic activety. It is very exciting and amazing.   The high rate
246   of this reaction shows that JAL-TA9 had high activity, potentially higher than that of JAL-AK22,
247   which had not completely degraded even after 5 days of incubation (Figure 3 and 5).

248   The most important question is an apprehension about the contamination of some bacteria. The
249   proteolytic activity obtained from the reaction mixture after filtration proved that the proteolysis
250   was not caused by the contamination of some bacteria but caused by JAL-TA9 (Figure 5S and Figure
251   9). In addition, JAL-TA9 showed the proteolytic activity after boiling with hot water or treatment
252   with organic solvents such as CH_3CN, CH_3OH, DMSO and TFA (data not shown). These data
253   supported the existence of the proteolytic activety of JAL-TA9 itself.

254   The aim of using HSA at first is to monitor the cleavage reaction against the major protein in
255   blood. We also examined the proteolytic activity of JAL-TA9 against 5 native proteins, γ-globulin
256   (γ-G), rabbit immuno-globulin G (IgG), cytochrome C (Cyt-C), lysozyme (Lys) and HSA, by
257   SDS-PAGE with silver staining and HPLC, and none were cleaved by JAL-TA9 (Figure S10). These
258   data suggest that JAL-TA9 may not display serious side effects.   Interestingly, HSA enhanced the
259   auto-proteolytic activity of JAL-AK22 and JAL-TA9. However, the effect of HSA is not well
260   understood, but may involve the conformational stabilization of JAL-AK22 and JAL-TA9. AEBSF
261   inhibits the proteolytic activity of JAL-TA9 [9], suggesting the special conformation composed of
262   catalytic triad to show the serine protease-like activity [10, 11]. The conformational study by NMR
263   supported the formation of catalytic triad [12]. This conformation may be very flexible and stabilized
264   by the interaction of HSA. The kinetic parameters indicated that the proteolytic activety of JAL-TA9
265   is weaker than that of protein enzyme such as chymotrypsin due to lack of binding site (Figure 12).
266   In contrast, JAL-TA9 is easy to handle comparison of protein enzyme because of its stability.

267   Although Tob/BTG proteins are reported as the unstable proteins and difficult to purify
268   probably due to their instability [5], whether any Tob protein itself has proteolytic activity remains
269   unknown. Taken together our finding, it is suggested that Tob/BTG proteins may have proteolytic
270   activity. In addition, our study suggests the possibility that other peptide enzymes derived from
271   degradable and unstable proteins could inform research strategies not only in the field of
272   enzymology but also in molecular biology. The remaining important question is what the substrate
273   of JAL-TA9 is. We now almost finish the investigation of the substrate specificity [13] and
274   structure-activity relationship [14].

275
276
277
278

279

280 **4. Materials and Methods**

281 *4.1 Chemical synthesis of peptides*

282　　Peptides were synthesized from Fmoc-protected L-amino acid derivatives according to the
283 method described by Kojima *et al* [15]. using an automated peptide synthesizer (model 433A,
284 Applied Biosystems, California, U. S. A., 0.1 mmol scale with preloaded resin). After deprotection
285 according to the manufacturer's protocol, each peptide was purified using reversed-phase HPLC
286 (Capcell Pak C18 column, SG, 10 or 15 mm i.d. x 250 mm; Shiseido Co., Ltd. Japan) with a linear
287 elution gradient from 0.1 % trifluoro acetic acid (TFA) to 50 % or 70 % CH_3CN containing 0.1 % TFA
288 over 30 min. The flow rate was set at 3.0 or 6.0 mL/min. The primary peak fractions were collected
289 and then lyophilized. The purity of the synthetic peptides and the progress of the enzymatic
290 reaction were confirmed by analytical reversed-phase HPLC (Capcell Pak C18 column, MGII, 4.6
291 mm i.d. x 150 mm; Shiseido Co. Ltd., Japan) at a flow rate of 1.0 mL/min with a linear elution
292 gradient from 0.1 % TFA to 70 % CH_3CN containing 0.1 % TFA. The column eluate was monitored
293 with a photodiode-array detector (SPD-M20A; Shimadzu, Japan). Each purified peptide was
294 characterized by ESI-MS using a Qstar Elite Hybrid LC-MS/MS system [15].

295

296 *4. 2 Preparation of recombinant MMP-7 and identification of proteolytic activity*

297　　The recombinant human proMMP-7 was prepared according to our previous report [1].
298 Briefly, proMMP-7 was overexpressed in *Escherichia coli* as a recombinant zymogen (31 kDa), the
299 C-terminus of which bears artificial hexa-histidines. The insoluble fraction of the *E. coli* extract
300 including u-proMMP-7 was purified in a single step using Ni-NTA resin after solubilization of the
301 precipitates with 8 M urea. The resin-bound recombinant protein was refolded into a f-proMMP-7
302 by reducing the urea concentration in a stepwise manner. The f-proMMP-7 is activatable by
303 *p*-amino-phenylmercuric acetate (APMA) or trypsin in an autocatalytic manner. The proteolytic
304 activity of the actMMP-7 was confirmed by a microplate reader assay using the fluorescence
305 quenching　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　substrate,
306 7-methoxycoumarin-4-yl-acetyl-Pro-Leu-Gly-Leu-[N^3-(2,4-dinitrophenyl)-L-2,3-diaminopropionyl]-
307 Ala-Arg-NH_2 (3163-v: Peptide Institute, Osaka, Japan). Briefly, 60 μL of assay buffer for MMP-7
308 (final conc.: 50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 10 mM $CaCl_2$; 5 μM $ZnCl_2$; 0.05 % Brij-35; 3 mM
309 NaN_3) containing an appropriate amount of MMP-7 (30 μL) and 20 μL of a 1 mM peptide solution
310 (final conc., 0.2 mM) was preincubated in each well of a 96-well microplate at 37 °C for 15 min, and
311 then 180 μL of the fluorescence quenching substrate (3163-v, final conc., 2.5 μM) was added to
312 initiate the proteolytic reaction. The fluorescence intensity was measured at 320 nm for excitation
313 and 390 nm for emission every 15 min for 2 hrs or every 30 min for 6 hrs without interrupting the
314 reaction using a fluorescence microplate reader (FP8300, JASCO, Tokyo, Japan). To identify the
315 proteolytic activity of JAL-TA9, u-proMMP-7 or f-proMMP7 was used in place of actMMP-7
316 (Scheme 1).

317

318   *4. 3 Analysis of proteolytic activity and determination of cleavage sites*

319   JAL-TA9 (final conc., 0.2 mM) was individually incubated with or without the fragment
320   peptide derived from the prodomain of MMP-7 (final conc., 0.05 mM) in the presence or absence of
321   human serum albumin (HSA) (final conc., 0.025 % w/v) in PBS (pH 7.4) at 37 °C.   A portion of the
322   reaction mixture was analyzed in a time-dependent manner on the analytical HPLC system
323   described above.   The peak fractions monitored at 220 nm were collected into microtubes
324   (Eppendorf Safe-Lock Tubes, 1.5 mL).

325   After lyophilization, the appropriate quantity of 36 % CH_3CN containing 0.1 % HCOOH was
326   determined based on the chromatographic peak height and added with stirring by an automatic
327   mixer.   The cleavage site were determined by ESI-MS using the flow injection method with 70 %
328   CH_3CN containing 0.1 % HCOOH on a Qstar Hybrid LC-MS/MS system (ABI). The flow rate was set
329   at 0.1 mL/min [15].

330

331   *4.4 Kinetic parameters*

332   The enzymatic activity of JAL-TA9 was measured using MMP18-33 or MMP18-40 as
333   substrates at 4 different final concentrations (50, 100, 200 and 400 μM).   JAL-TA9 was incubated
334   with MMP18-33 or MMP18-40 in the same manner as in the determination of the proteolytic activity
335   described above.   The reaction mixture (10 μL) was analyzed on an analytical HPLC at the initial
336   time and after 24 hrs of incubation.   The peak heights of MMP18-33 and MMP18-40 gave linear fits
337   on the Lineweaver-Burk plots.

338   **5. Conclusions**

339   JAL-TA9 possesses serine protease-like activity [9-11] and activates proMMP-7 by cleaving the
340   prodomain region.   To the best of our knowledge, protease-like activity has never been reported in
341   such small synthetic peptides, and we therefore propose that these peptides with protease-like
342   activity, such as JAL-TA9, be called Catalytides (catalytic peptides).   We expect that our findings
343   will stimulate the development of novel Catalytides and related applications.

344   **6. Patents**

345   T. Yamamoto, T. Akizawa 2016 NOVEL PEPTIDE Patent Pending No US62/275,599, and 2016
346   NOVEL HYDROLASE-LIKE PEPTIDE AND ITS USE Patent Pending No JP2016-068496

347

348   **Supplementary Materials:** The following are available online at www.mdpi.com/link, Figure S1: Amino acid
349   sequences of Tob1 and MMP-7, S2: Auto-proteolytic activity of JAL-AK22 and JAL-TA9, S3: Structure-activity
350   relationship of JAL-TA9 derivative peptides, S4: Determination of the optimal conditions for the
351   auto-proteolytic activity of JAL-TA9, S5: Auto-proteolytic activity of JAL-TA9 with or without filtration, S6:
352   Cleavage reactions of MMP-7 fragment peptides by JAL-TA9, S7: Identification of cleavage sites , S8:
353   Identification of the complex with JAL-TA9 and AEBSF, S9: Kinetic parameters, S10: Proteolytic activity of
354   JAL-TA9 against native proteins.

355

356   **Acknowledgments:** This work was supported by JSPS KAKENHI Grant Numbers 15K07908. We gratefully
357   thank to Dr. Aya Kojima for technical supports, Dr. Mitsuaki Yoshida of Cancer Institute and Dr. Hidemitsu
358   Pan-Hou for invaluable discussion and suggestion.

359

Author Contributions: T.A. were responsible for experimental design and data interpretation. T.A. and R.N. mainly contributed to writing and reversing the manuscript. M.T. was conducted screening of proteolytic peptide. R.N. were conducted all experiments, especially HPLC analysis and determination of cleavage sites. R.N., M.K. and Y.H. were contributed to MS analysis. M.K. and R.N. analyzed JAL-TA9 conformation by Computer modeling.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Itoh, M.; Masuda, K.; Ito, Y., Akizawa, T.; Yoshioka, M.; Imai, K.; Okada, Y.; Sato, H.; Seiki, M. Purification and Refolding of Recombinant Human proMMP-7 (pro-Matrilysin) Expressed in Escherichia coli and Its Characterization. *J. Biochem.* **1996**, 119, 667-673

2. Oku, N.; Matsukawa, M.; Yamakawa, S.; Asai, T.; Yahara, S.; Hashimoto, F.; Akizawa, T. Inhibitory Effect of Green Tea Polyphenols on Membrane-Type 1 Matrix Metalloproteinase, MT1-MMP. *Biol. Pharm. Bull.* **2003**, 26(9) 1235-1238

3. Taniguchi, M.; Matsumura, K.; Nakamura, R.; Kojima, A.; Konishi, M.; Akizawa, T. MMP-7 cleaves amyloid β fragment peptides and copper ion inhibits the degradeation. *Biometals.* **2017**, 30, 797-807, DOI. 10.1007/s10534-017-0048-4

4. Matsuda, S.; Kawamura-Tsuzuku, J.; Ohsugi, M.; Yoshida, M.; Emi, M.; Nakamura, Y.; Onda, M.; Yoshida, Y.; Nishiyama, A.; Yamamoto, T. Tob, a novel protein that interacts with p185erbB2, is associated with anti-proliferative activity. *Oncogene* **1996**, 12, 705-713 DOI. PubMed: 8632892

5. Horiuchi, M.; Takeuchi, K.; Noda, N.; Muroya, N.; Suzuki, T.; Nakamura, T.; Kawamura-Tsuzuku, J.; Takahasi, K.; Yamamoto, T.; Inagaki, F. Structural Basis for the Antiproliferative Activity of the Tob-hCaf1 Complex. *JBC.* **2009**, 284(19), 13244-13255, DOI. 10.1074/jbc.M809250200

6. Winkler, G.S. The Mammalian Anti-Proliferative BTG/Tob Protein Family. *J. Cell. Physiol.* **2010**, 222, 66-72, DOI. 10.1002/jcb.21919.

7. Kojima, A.; Konishi, M.; Noshi, M.; Akizawa, T. Finding of the chaperone peptide. *Peptide Science 2008*, **2009**, 277-280, Proceedings of The 53th Japanese Peptide Symposium, The official Journal of Japanese Peptide Society

8. Crabbe, T.; Willenbrock, F.; Eaton, D.; Hynds, P.; Carne, A. F.; Murphy, G.; Docherty, A. J. Biochemical characterization of matrylysin. Activation conformers to the stepwise mechanisms proposed for other matrix metalloproteinases. *Biochemistry.* **1992,** 31, 8500-8507

9. Nakamura, R.; Kojima, A.; Taniguchi, M.; Konishi, M.; Tokumasu, M.; Yamamoto, T.; Akizawa, T. THE NOVEL FINDING OF SERINE PROTEASE-LIKE PEPTIDE. *Peptide Science 2016*,**2017**, Proceedings of The 45th Japanese Peptide Symposium, The official Journal of Japanese Peptide Society, Tokto

10. Enrico Di Cera. Serine Proteases. *IUBMB Life* **2009**, 61(5), 510-515, DOI. 10.1002/jub.186

11. Hedstrom, L. Serine Protease Mechanism and Specificity. *Chem. Rev.* **2002**, 102, 4501-4523

12. Nakamura, R.; Konishi, M.; Tanaka, R.; Taniguchi, M.; Kojima, A.; Yamamoto, T.; Akizawa, T. STRUCTURAL ANALYSIS OF THE NOVEL HYDROLASE-LIKE PEPTIDE (JAL-TA9). *Peptides 2016.* **2016**, 111-112, Proceedings of 34th European Peptide Symposium 2016 & 8th International Peptide Symposium, Leipzig

13. Akizawa, T.; Nakamura, R.; Kojima, A.; Konishi, M.; Taniguchi, M.; Tokumasu, M.; Yamamoto, T. FINDING OF THE NOVEL HYDROLASE-LIKE PEPTIDE (JAL-TA9) DIGESTING Aβ PROTEIN. *Peptides 2016.* **2016**, 28-29, Proceedings of 34th European Peptide Symposium 2016 & 8th International Peptide Symposium, Leipzig

14. Nakamura, R.; Hatakawa, Y.; Konishi, M.; Taniguchi, M.; Akizawa, T. STRUCTURE-ACTIVITY RELATIONSHIP OF 5-MER PEPTIDES DERIVED FROM JAL-TA9. *Peptide Science 2017,* **2018**, Proceedings of The 53th Japanese Peptide Symposium, The official Journal of Japanese Peptide Society, Kyoto

15. Kojima, A.; Konishi, M.; Akizawa, T. Prion Fragment Peptides Are Digested with Membrane Type Matrix Metalloproteinases and Acquire Enzyme Resistance through Cu²⁺-binding. *Biomolecules* **2014**, 4, 510-526 (2014); DOI. 10.3390/biom4020510